InsiderTrades

Form 4 for JANX Janux Therapeutics, Inc.

Accepted 2025-03-05 00:00:00 ET · period of report 2025-03-03 · accession 0001415889-25-007104 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-03-05 2025-03-03 JANX Meyer Andrew Hollman Chief Business Off M - OptEx $4.21 +3,334 85.5K +4% +$14.0K
DM 2025-03-05 2025-03-03 JANX Meyer Andrew Hollman Chief Business Off S - Sale+OE $32.14 -3,334 83.0K -4% -$107.2K
D 2025-03-05 2025-03-03 JANX Meyer Andrew Hollman Chief Business Off M - OptEx $0.00 -3,334 94.0K -3% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-03-03 M A 3,334 $4.21 85,473 D — —
2 Common Common Stock 2025-03-03 S D 901 $32.85 82,139 D — — (F3) The weighted average sale price for the transaction reported was $32.8509 and the range of prices were between $32.53 and $33.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3 Common Common Stock 2025-03-03 S D 2,433 $31.88 83,040 D — — (F2) The weighted average sale price for the transaction reported was $31.8848 and the range of prices were between $31.50 and $32.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
4 Derivative Stock Option (right to buy) 2025-03-03 M D 3,334 $0.00 93,999 D $4.21 · — to 2031-03-09 3,334 Common Stock (F4) Immediately exercisable.